Core product sales increase year-on-year


2020-01-16 20:26:20Beijing News Reporter: Wang Kara Editing: Yue Qingxiu
Original copyright prohibits commercial reprintAuthorization

Core product sales increase year-on-year

2020-01-16 20:26:20Beijing News Reporter: Wang Kara

Beijing News (Reporter Wang Kara) On January 16, Yiming Bio released the 2019 performance forecast. During the reporting period, the company’s net profit attributable to shareholders of the listed company is expected to be RMB 32,831,500 to RMB 40,480,800, a year-on-year increase of 30%. -60%.

Zh

According to Yiming Medicine, during the reporting period, the company proactively adapted to changes in the pharmaceutical environment and policy adjustments around strategic goals, improved marketing network construction, continued to develop channels and terminals, increased academic promotion, fully leveraged product advantages, and maintained steady performance. increase. Main products: Carbetocin injection (Xinuoshu), miglitol tablets (Aotian Ping), montmorillonite powder (Bei Yiping), Hongjinxiaojie tablets (Methodantan), domperidone tablets ( Year-on-year sales of products such as Weidolin have increased to varying degrees.

Zh

Headquartered in Lhasa National Economic and Technological Development Zone, Tibet, Yiming Pharmaceutical has long been committed to the development and research of core products in the treatment of chronic diseases such as diabetes and cardiovascular diseases in the elderly and gynecological and obstetrics.

Zh

Yiming Pharmaceutical’s 2019 semi-annual report and third quarterly report show that the company’s net profit attributable to shareholders of listed companies in the first half of the year fell by 23.07% year-on-year to 11.9344 million yuan; the third-quarter net profit increased by 180.60% year-on-year in the first half of the year The decline in net profit “filled in the pits” caused the first three quarters of net profit attributable to shareholders of listed companies to increase by 42.56% year-on-year, and net profit after non-deduction increased by 77.98% year-on-year.

Zh

In the first three quarters of this year, the sales expenses of Yiming Pharmaceutical decreased by 48.99% year-on-year to 80.926 million yuan. Yiming Pharmaceuticals said that it was mainly due to changes in the business model and accounting method of cooperative products operated as agents after the implementation of the “two-vote system” policy. The company charged the producers for promotion service fees and listed them as promotion Service income, meanwhile, the company’s marketing expenses for the part of the cooperative products covered to the terminal are listed as the cost of promotion services.

Editing Yue Qingxiu Proofreading Lu Qian

Click to load more

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *